NT-PROBNP As A Prognostic Marker: Correlation Between Biomarker Levels And Severity, Hospitalization Rate, And Mortality In Heart Failure Patient
DOI:
https://doi.org/10.63682/jns.v14i32S.8157Keywords:
NT-proBNP, heart failure, prognosis, hospitalization, mortality, biomarker, ICU risk, cutoff value, ROC analysis, internal medicine, clinical governance, digital health monitoringAbstract
This study, conducted at the Department of General Medicine, Naraina Medical College and Research Centre, Kanpur, from January 2024 to January 2025 to investigate the prognostic importance of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) levels in patients admitted to the internal medicine department. NT-proBNP has emerged as an essential biomarker not only for the diagnosis of heart failure but also for predicting outcomes in both cardiac and non-cardiac conditions. This retrospective analysis involved 600 patients, who were categorized into two outcome groups: those who were discharged and those who were either transferred to the intensive care unit or died during hospitalization. NT-proBNP levels were significantly higher in the ICU/Deceased group compared to the discharged group (mean: 3732.15 ± 7297 vs. 10923 ± 12572 pg/ml; p < 0.001). Receiver Operating Characteristic (ROC) analysis identified a cutoff point of >1826 pg/ml, above which the risk of ICU admission or death increased 5.44-fold. Subgroup analysis showed that elevated NT-proBNP levels were a significant independent predictor of poor prognosis in patients with and without cardiac symptoms (p < 0.001). The findings underscore NT-proBNP’s value as an early warning biomarker to support clinical decision-making, optimize resource allocation, and guide personalized treatment strategies. Incorporating NT-proBNP into standardized e-health monitoring and triage systems may reduce delays in critical care, improve hospital efficiency, and support outcome-focused healthcare governance. These results demonstrate the potential of NT-proBNP to bridge the gap between diagnostic precision and public health policy, enhancing both clinical outcomes and infrastructure utilization
Downloads
References
Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): Measurement and relevance in heart fail- ure. Vasc Health Risk Manag 2010;6:411–8. [CrossRef ]
Yardan T, Baydın A, Demircan S, Aygün D, Doğanay Z. The role of B-type natiuratic peptide in heart failure. OMU Tıp Derg [Article in Turkish] 2004;21:188–94.
Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Or- donez-Llanos J, Santalo-Bel M, et al. NT-proBNP Testing for di- agnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330–7. [CrossRef ]
Núúez J, Núúez E, Robles R, Bodí V, Sanchis J, Carratalá A, et al. Prognostic value of brain natriuretic peptide in acute heart failure: Mortality and hospital readmission. Rev Esp Cardiol [Article inSpanish] 2008;61:1332–7. [CrossRef ]
Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022;27:625–43. [CrossRef ]
Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker test- ing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. Clin Chim Acta Int J Clin Chem 2015;443:17–24. [CrossRef ]
Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J InternMed 2008;264:166–76. [CrossRef ]
Idris I, Hill R, Ross I, Sharma JC. N-terminal probrain natriuretic peptide predicts 1-year mortality following acute stroke: Possible evi- dence of occult cardiac dysfunction among patients with acute stroke. Age Ageing 2010;39:752–5. [CrossRef ]
Cao C, Yang L, Nohria A, Mayer EL, Partridge AH, Ligibel JA. As- sociation of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors. J Natl Cancer Inst 2024;116:938–47. [CrossRef ]
Maviş O, Öksüz S, Boyuk B, Bulut U, Zengi O, Kapucu K. Impor- tance of diastolic dysfunction and Nt-ProBNP measurement for ıdentification of volume load in predialysis chronic renal failure pa- tients. South Clin Ist Euras 2023;34:36–41.
Benmachiche M, Marques-Vidal P, Waeber G, Méan M. In-hospi- tal mortality is associated with high NT-proBNP level. PLoSOne 2018;13:e0207118. [CrossRef ]
Kotanidou A, Karsaliakos P, Tzanela M, Mavrou I, Kopterides P, Pa- padomichelakis E, et al. Prognostic importance of increased plasma amino-terminal pro-brain natriuretic peptide levels in a large noncar- diac, general intensive care unit population. Shock 2009;31:342–7. [CrossRef]
Nowak A, Breidthardt T, Christ-Crain M, Bingisser R, Meune C, Tanglay Y, et al. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia. Chest 2012;141:974–82. [CrossRef ]
Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M; ADHERE Scientific Advisory Committee and Investigators. Ad- mission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J AmCollCardiol 2007;49:1943–50. [CrossRef ]
Waldum B, Stubnova V, Westheim AS, Omland T, Grundtvig M, Os. Prognostic utility of B-type natriuretic peptides in patients with heart failure and renal dysfunction. Clin Kidney J 2013;6:55–62. [CrossRef ]
Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated my- ocardial dysfunction: Diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006;129:1349–66. [CrossRef ]
Witthaut R, Busch C, Fraunberger P, Walli AK, Pilz G, Stuttmann N, et al. Plasma natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associ- ated left ventricular dysfunction. Intensive Care Med 2003;29:1696– 702. [CrossRef ]
Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Chris- tensen JH. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol 2009;71:380-6. [CrossRef ]
Blyth KG, Groenning BA, Mark PB, Martin TN, Foster JE, Steed- man T, et al. NT-proBNP can be used to detect right ventricu- lar systolic dysfunction in pulmonary hypertension. Eur Respir J 2007;29:737–44. [CrossRef ]
Su X, Lei T, Yu H, Zhang L, Feng Z, Shuai T, et al. NT-proBNP In different patient groups of COPD: A systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2023;18:811–25. [CrossRef ]
Gimeno E, Gómez M, González JR, Comín J, Alvarez-Larrán A, Sánchez-González B, et al. NT-proBNP: A cardiac biomarker to as- sess prognosis in non-Hodgkin lymphoma. LeukRes 2011;35:715–20. [CrossRef ]
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
